他汀类药物对于COPD患者肺功能影响的荟萃分析

doi:10.5246/jcps.2018.04.029

中国药学(英文版) ›› 2018, Vol. 27 ›› Issue (4): 281-288.DOI: 10.5246/jcps.2018.04.029

• 【药事管理与临床药学专栏】 • 上一篇下一篇

他汀类药物对于COPD患者肺功能影响的荟萃分析

周祎, 王军^*, 张龙^*

南京大学医学院附属鼓楼医院急诊科, 江苏南京 210008

收稿日期:2018-01-15 修回日期:2018-03-12 出版日期:2018-04-30 发布日期:2018-03-31
通讯作者: Tel.: +86-025-83106666-60184, E-mail: wangjunnjglyy@163.com; dragonglh@126.com
基金资助:
The Science and Technology Project of Traditional Chinese Medicine of Jiangsu Province (Grant No. YB2015073, Wang J).

Statin therapy on pulmonary function in patients with COPD: a meta-analysis of randomized controlled trials

Yi Zhou, Jun Wang^*, Long Zhang^*

Department of Emergency Medicine, Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, 210008, China

Received:2018-01-15 Revised:2018-03-12 Online:2018-04-30 Published:2018-03-31
Contact: Tel.: +86-025-83106666-60184, E-mail: wangjunnjglyy@163.com; dragonglh@126.com
Supported by:
The Science and Technology Project of Traditional Chinese Medicine of Jiangsu Province (Grant No. YB2015073, Wang J).

摘要/Abstract

摘要：

本文旨在系统评价他汀类药物对于慢性阻塞性肺病(COPD)患者肺功能的影响。通过计算机检索Medline, EMBASE和The Cochrane Library数据库, 检索时限均为从建库至2017年1月, 收集COPD患者使用他汀类药物的随机对照试验。采用Stata 12.0软件进行Meta分析。结果共纳入8项研究, 534例患者。Meta分析结果显示:他汀类药物没有显著改善FEV1、FEV1/FVC、6分钟步行距离、心率以及C反应蛋白, 但活动平板运动时间却有显著提高。亚组分析显示普伐他汀能够显著改善FEV1/FVC。本研究结果提示: 他汀类药物没有显著改善COPD患者的肺功能, 基于目前的研究结果,不推荐COPD患者常规使用他汀类药物(合并心血管疾病危险因素的患者除外)。

关键词: 他汀类药物, 肺功能, COPD, Meta分析

Abstract:

In thecurrent meta-analysis, we aimed to investigate the therapeutic effects of statins on pulmonary function inpatients with chronic obstructive pulmonary disease (COPD).MEDLINE, EMBASE and Cochrane Central Register of clinical trials were systematically searched until January 2017 for RCTs of statins. Only trials with COPD patients were included.The I²statistic was used to measure heterogeneity between trials and calculated mean differences for pulmonary function parameters with fixed-effect meta-analysis.Eighteligible studies with 534 participants were identified. Statin therapy had no remarkable influence on FEV1 (SMD –0.01, 95% CI –0.204 to 0.184, I²=0.0%, P = 0.922, n = 409), FEV1/ FVC (SMD 0.163, 95% CI –0.044to 0.369, I²=0.0%, P = 0.123, n = 364), 6MWD, heart rate or CRP. However, exercise time on treadmill was remarkably improved by statin therapy (SMD 1.271, 95% CI 0.930 to 1.612, I²=0.0%, P = 0.000, n = 160). Subgroup analysis showed significant, ameliorative effect of pravastatin on FEV1/FVC (SMD 0.362, 95% CI 0.049 to 0.674, I²=0.0%, P = 0.023).The results of this meta-analysis showed non-significant effect of statins on pulmonary function in COPD patients. Based on the studies reviewed, it is not recommended to prescribe statins for COPD patients without CVD risk factors due to lack of clearly defined benefit.

Key words: Statins, Pulmonary function, COPD, Meta-analysis

中图分类号:

R974

Supporting:

周祎, 王军, 张龙. 他汀类药物对于COPD患者肺功能影响的荟萃分析[J]. 中国药学(英文版), 2018, 27(4): 281-288.

Yi Zhou, Jun Wang, Long Zhang. Statin therapy on pulmonary function in patients with COPD: a meta-analysis of randomized controlled trials[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(4): 281-288.

参考文献

[1] Kuklina, E.V.; Carroll, M.D.; Shaw, K.M.; Hirsch, R. Trends in high LDL cholesterol, cholesterol-lowering medication use, and dietary saturated-fat intake: United States, 1976-2010. NCHS Data Brief. 2013, 117, 1-8.

[2] Desai, C.S.; Martin, S.S.; Blumenthal, R.S. Non-cardiovascular effects associated with statins. BMJ. 2014, 349, g3743.

[3] Murphy, S.L.; Xu, J.; Kochanek, K.D. Deaths: final data for 2010. Natl. Vital. Stat. Rep. 2013, 61, 111-117.

[4] Yeganeh, B.; Wiechec, E.; Ande, S.R.; Sharma, P.; Moghadam, A.R.; Post, M.; Freed, D.H.; Hashemi, M.; Shojaei, S.; Zeki, A.A.; Ghavami, S. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol. Ther. 2014, 143, 87-110.

[5] Wang, M.T.; Lo, Y.W.; Tsai, C.L.; Chang, L.C.; Malone, D.C.; Chu, C.L.; Liou, J.T. Statin use and risk of COPD exacerbation requiring hospitalization. Am. J. Med. 2013, 126, 598-606.

[6] Ingebrigtsen, T.S.; Marott, J.L.; Nordestgaard, B.G.; Lange, P.; Hallas, J.; Vestbo, J. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax. 2015, 70, 33-40.

[7] Lee, T.M.; Lin, M.S.; Chang, N.C. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am. J. Cardiol. 2008, 101, 530-535.

[8] Lee, T.M.; Chen, C.C.; Shen, H.N.; Chang, N.C. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin. Sci. 2009, 116, 497-505.

[9] Kaczmarek, P.; Sladek, K.; Skucha, W.; Rzeszutko, M.; Iwaniec, T.; Dziedzina, S.; Szczeklik, A. The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease. Pol. Arch. Med. Wewn. 2010, 120, 11-17.

[10] Moosavi, S.A.; Raji, H.; Faghankhani, M.; Yazdani, R.; Esmaeili, M. Evaluation of the Effects of Atorvastatin on the Treatment of Secondary Pulmonary Hypertension due to Chronic Obstructive Pulmonary Diseases: A Randomized Controlled Trial. Iran. Red. Crescent. Med. J. 2013, 15, 649-654.

[11] Ghobadi, H.; Lari, S.M.; Pourfarzi, F.; Mahmoudpour, A.; Ghanei, M. The effects of atorvastatin on mustard-gas-exposed patients with chronic obstructive pulmonary disease: A randomized controlled trial. J. Res. Med. Sci. 2014, 19, 99-105.

[12] Neukamm, A.; Hoiseth, A.D.; Einvik, G.; Lehmann, S.; Hagve, T.A.; Søyseth, V.; Omland, T. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial. J. Intern. Med. 2015, 278, 59-67.

[13] John, M.E.; Cockcroft, J.R.; McKeever, T.M.; Coward, W.R.; Shale, D.J.; Johnson, S.R.; Thornton, J.G.; Harrison, T.W.; Knox, A.J.; Bolton, C.E. Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: a randomized controlled trial. Int. J. Chron. Obstruct. Pulmon. Dis. 2015, 10, 211-221.

[14] Balaguer, C.; Peralta, A.; Ríos, A.; Iglesias, A.; Valera, J.L.; Noguera, A.; Soriano, J.B.; Agustí, A.; Sala-Llinas, E. Effects of simvastatin in chronic obstructive pulmonary disease: Results of a pilot, randomized, placebo-controlled clinical trial. Contemp. Clin. Trials. 2016, 2, 91-96.

[15] Criner, G.J.; Connett, J.E.; Aaron, S.D.; Albert, R.K.; Bailey, W.C.; Casaburi, R.; Cooper, JA. Jr.; Curtis, J.L.; Dransfield, M.T.; Han, M.K.; Make, B.; Marchetti, N.; Martinez, F.J.; Niewoehner, D.E.; Scanlon, P.D.; Sciurba, F.C.; Scharf, S.M.; Sin, D.D.; Voelker, H.; Washko, G.R.; Woodruff, P.G.; Lazarus, S.C.; COPD Clinical Research Network; Canadian Institutes of Health Research. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N. Engl. J. Med. 2014, 370, 2201-2210.
[16] Criner, G.J.; Bourbeau, J.; Diekemper, R.L.; Ouellette, D.R.; Goodridge, D.; Hernandez, P.; Curren, K.; Balter, M.S.; Bhutani, M.; Camp, P.G.; Celli, B.R.; Dechman, G.; Dransfield, M.T.; Fiel, S.B.; Foreman, M.G.; Hanania, N.A.; Ireland, B.K.; Marchetti, N.; Marciniuk, D.D.; Mularski, R.A.; Ornelas, J.; Road, J.D.; Stickland, M.K. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015, 147, 894-942.

他汀类药物对于COPD患者肺功能影响的荟萃分析

Statin therapy on pulmonary function in patients with COPD: a meta-analysis of randomized controlled trials

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张格第, 刘庚鑫, 晏子友. 基于meta分析和网络药理学理冲汤(丸)治疗癌症的疗效评价及作用机制研究[J]. 中国药学(英文版), 2023, 32(9): 720-735.
[2]	彭词艳, 陈景, 李斯妮, 李健和, 彭六保. 哌柏西利联用来曲唑对比多西他赛联用表柔比星一线治疗晚期乳腺癌的循证药物经济学评价[J]. 中国药学(英文版), 2023, 32(3): 214-222.
[3]	李雅静, 白雅雯, 杜宇, 严长宏, 麻春杰, 孙丽宁, 卜凤跃, 严昊阳. 玉屏风散治疗慢性肾小球肾炎的临床疗效评价及作用机制研究[J]. 中国药学(英文版), 2023, 32(12): 1006-1026.
[4]	李敏, 常路路, 岳向峰, 杜书章. ACEI联合丹参酮治疗肺心病急性加重期的疗效和安全性的meta分析[J]. 中国药学(英文版), 2022, 31(11): 853-865.
[5]	孙颖光, 岳圆圆, 邵杰敏, 高萌, 邓艳茹, 冯运佳. 康复新液与西瓜霜治疗复发性口腔溃疡疗效比较的meta分析[J]. 中国药学(英文版), 2022, 31(10): 761-772.
[6]	覃思蓓, 贾彤, 扶宇, 李俊蕾, 张欣怡, 祝春素, 梁广楷, 聂小燕, 史录文, 崔一民. CYP3A4基因多态性对心脑血管疾病患者氯吡格雷响应影响的Meta分析[J]. 中国药学(英文版), 2021, 30(9): 762-772.
[7]	宋瑶, 支小飞, 赵洪瑜, 周兴芹, 陈文娟, 向田直史, 林清, 季斌. 他汀类药物的使用与胰腺癌发生风险的荟萃分析[J]. 中国药学(英文版), 2019, 28(12): 855-867.
[8]	张林, 丁洁卫, 王阳, 金晓宣, 葛伟东, 黄淑婷, 李玉婷. 埃罗妥珠单抗治疗难治性/复发性多发性骨髓瘤临床试验效果的Meta分析[J]. 中国药学(英文版), 2017, 26(7): 528-533.
[9]	肖锐锐, 徐秀琴, 孙磊, 方晓磊, 肖鹏. 降心率药物伊伐布雷定安全性的系统评价[J]. 中国药学(英文版), 2017, 26(5): 379-389.
[10]	张林, 金晓宣, 黄淑婷, 徐雯宇, 丁洁卫. 卡非佐米及其组合药物在治疗多发性骨髓瘤的有效性及安全性分析[J]. 中国药学(英文版), 2017, 26(3): 222-229.
[11]	赵德华, 楚明明, 陈静, 王继生. 吉西他滨标准剂量30分钟快速输注与低剂量延时输注治疗进展期非小细胞肺癌的Meta分析[J]. 中国药学(英文版), 2017, 26(10): 763-770.
[12]	韩茹, 安雅晶, 赵荣生. α-酮酸对慢性肾脏病患者的附加作用: 一项随机对照试验的系统评价和meta分析[J]. 中国药学(英文版), 2017, 26(1): 63-75.
[13]	张亚同, 梁欣, 董凡, 郑子恢, 胡欣. 中国心血管病患者中STX4 基因多态性对华法林作用的影响[J]. 中国药学(英文版), 2016, 25(9): 683-689.
[14]	饶欣, 王长连, 许雄伟, 黄品芳, 王航, 林璐. 盐酸羟考酮缓释片与硫酸吗啡缓释片的临床疗效安全性对比[J]. 中国药学(英文版), 2016, 25(5): 387-394.
[15]	胡琴, 唐惠林, 邵宏. 基于肠促胰素药物治疗2型糖尿病合并非酒精性肝病的疗效和安全性的系统评价和meta分析[J]. 中国药学(英文版), 2016, 25(3): 206-214.